Dan Budwick
@DanBudwick
Founder/CEO, @1ABMedia. Brand builder & C-suite advisor for biotechs and VCs. Secretary/Director, LJ Piniella Foundation. Jersey guy/NY sports fan living in FL
8 years of @1ABMedia. 17 FTEs - an amazing group of teammates I'm honored to be in the trenches with every day. A network of subcontractors and colleagues who specialize in areas we don't. The most badass client roster in biotech. And I get to do this for work. How lucky am I.
In honor of our 8th anniversary today, our founder @DanBudwick reflects on the journey, how taking a leap of faith led to a life changing experience and the gratitude we share for our team and clients alike. Read the personal reflection below. linkedin.com/pulse/8-years-…
Let’s keep the optimism flowing, people. Welcome to the world, @DispatchBio!!!!
With solid tumors representing ~90% of cancers, Dispatch Bio is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform to help create a world where all #cancer patients can be cured. Learn more: dispatchbio.com/news/dispatch-…
Circular RNA startup Orbital unveils first monkey data as it enters in vivo CAR-T cell therapy race - endpoints.news/circular-rna-s… via @endpts @RLCscienceboss
Congrats to the team at Omega Funds on raising a $647M fund in this environment statnews.com/2025/07/21/bio… via @statnews @ADeAngelis_bio
“On current trend lines, if we’re not careful, [China] could pass us. They are not just borrowing our ideas and adapting them anymore—they’re coming up with new ideas. In fact, many heavily cited biotechnology research papers are being produced in China.”
Biotech has major implications for our economy and national security. I spoke with @ISSUESinST about how biotechnology can strengthen America’s warfighters, modernize agriculture, and enhance life sciences. issues.org/interview-sena…
Bravo to Apogee Tx $APGE team on its data announcement this morning. So far, APG777 exhibiting best in class profile - strong safety/efficacy with unparalleled dosing schedule. Excited to see this program continue in development! investors.apogeetherapeutics.com/news-releases/…
Today we announce a $38 million financing, including a $33M Series A led by Cerberus Ventures. This is an exciting moment for Syntis, accelerating our vision to revolutionize both chronic and #raredisease treatment through safe, effective oral therapies. businesswire.com/news/home/2025…
Read the details:neuron23.com/neuron23-annou… We are pleased to announce the closing of our Series D financing round and the dosing of the first patient in our global Phase 2 NEULARK clinical trial of NEU-411 in people with early #Parkinsons.
Today, we shared positive topline results for zidesamtinib in TKI pre-treated patients with advanced ROS1+ NSCLC from our global Phase 1/2 ARROS-1 clinical trial. Learn more here: investors.nuvalent.com/2025-06-24-Nuv…
$NUVL
Today, we shared positive topline results for zidesamtinib in TKI pre-treated patients with advanced ROS1+ NSCLC from our global Phase 1/2 ARROS-1 clinical trial. Learn more here: investors.nuvalent.com/2025-06-24-Nuv…
There’s definitely a biotech swag idea here.
The mission to Make America Healthy Again (MAHA) includes MABA — Make American Biotech Accelerate. President Trump showed in his first term what happens when you unlock American science — breakthroughs happen fast. Now, we’re going to do it again. We know the power of U.S.…
Cool partnership for @insitro with @INSIGHTeyehub on the world’s largest eye imaging bioresource containing 35 million eye images to use data at scale and machine learning to deepen our understanding of #neurodegenerative disease and related conditions. Check out the video.
When it comes to understanding disease, the eye is the window to the entire body. To mark #Alzheimers & Brain Awareness Month, #ENDALZ this June, we share a “behind-the-scenes” look at our latest collaboration that is leveraging the world’s largest imaging bioresource containing…
👏🏻👏🏻👏🏻👏🏻
Today, we announced the successful completion of a $66 million Series B financing that will propel the advancement of our pipeline of small-molecule therapeutics targeting both rare & common diseases. Thank you to our investors, partners & team. Read more: businesswire.com/news/home/2025…
$LLY $VERV
We announced today that Verve has entered into a definitive agreement to be acquired by Eli Lilly and Company. Lilly shares our determination and dedication to transform the treatment paradigm for the millions of patients worldwide living with cardiovascular disease, and we…
$BEAM
Beam announced new safety & efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease with severe vaso-occlusive crises, which will be shared this afternoon in a poster presentation at the EHA2025 Congress.
My daughter Kaiya just graduated and is headed to @SamfordU in the fall. Our team at @1ABMedia thought it would be fun to put together a video of advice from our team, whether you're graduating from high school or entering the real world. Leave your own advice in comments below!
Congrats to the #ClassOf2025! Whether you're graduating from high school or entering the "real world", keep your horizons wide & your stride confident. No path is the same, but a little advice never hurts, so take some from us. (Or don’t! It’s your journey now.)
We are pleased to share positive Phase 1 data of first-in-class once-monthly amylin candidate MET-233i, which was engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 RA candidate MET-097i. MET-233i demonstrated up to 8.4%…
I am a Tom Thibodeau fan. He brought this team back. I felt he gave every bit of himself and was always looking to improve. I will always be grateful for how far he brought the Knicks. They are relevant again. They are championship contenders again. The Knicks became winners…
In case you needed a smile this Tuesday: 10-month-old baby KJ, who received a bespoke gene-editing therapy after a six month scientific sprint - "graduated" from the hospital today and went HOME! YAY SCIENCE! Here's his story: wapo.st/451ZQjT
Marea co-founders Josh Lehrer & @ethanjweiss joined @ldtimmerman on The Long Run podcast to share insights into our unique approach to tackling #cardiometabolic diseases and what it takes to build a company around a game-changing idea. Tune in below. timmermanreport.com/2025/05/a-new-…